Drug Trial Radar · NCT05350072
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
275
Actual
Start
Jul 28, 2022
Primary completion
May 7, 2025
Study completion Jun 2, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)
Conditions
- Sjogren Syndrome
Interventions
VAY736Biological
ianalumab s.c.
PlaceboOther
placebo s.c.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in EULAR Sjogren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placeboTime frame: 48 weeks
Locations
77 sites in 18 countries. Site status is shown where the registry gives one.
Medvin Clinical Research
Van Nuys, California
West Broward Rheumatology Associates Inc
Tamarac, Florida
Indiana Univ School of Dentistry
Indianapolis, Indiana
Ochsner Health System
Baton Rouge, Louisiana
The John Hopkins Jerome L Greene Sjogren
Baltimore, Maryland
NYU Langone Hospital - Long Island
Mineola, New York
Carolina Arthritis Associates
Wilmington, North Carolina
STAT Research Inc
Dayton, Ohio
Altoona Center for Clin Res
Duncansville, Pennsylvania
Precision Comprehensive Research
Colleyville, Texas
Metroplex Clinical Research
Dallas, Texas
Baylor College Of Medicine
Houston, Texas
Houston Rheumatology and Arthrit
Katy, Texas
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Stockerau, Austria
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
Vitória, Espírito Santo, Brazil
Novartis Investigative Site
Juiz de Fora, Minas Gerais, Brazil
Novartis Investigative Site
Ribeirão Preto, São Paulo, Brazil
Novartis Investigative Site
Santiago, Santiago Metropolitan, Chile
Novartis Investigative Site
Santiago, Santiago Metropolitan, Chile
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Shenzhen, Guangdong, China
Novartis Investigative Site
Wuhan, Hubei, China
Novartis Investigative Site
Baotou, Inner Mongolia, China
Novartis Investigative Site
Hohhot, Inner Mongolia, China
Novartis Investigative Site
Nanchang, Jiangxi, China
Novartis Investigative Site
Shenyang, Liaoning, China
Novartis Investigative Site
Linyi, Shandong, China
Novartis Investigative Site
Taiyuan, Shanxi, China
Novartis Investigative Site
Xian, Shanxi, China
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Uherské Hradiště, Czechia
Novartis Investigative Site
Caen, France
Novartis Investigative Site
Dijon, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Marseille, France
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.